小剂量米非司酮治疗子宫肌瘤临床疗效分析

Analysis on clinical efficacy of low dose mifepristone for hysteromyoma

目的分析小剂量米非司酮治疗子宫肌瘤的临床疗效。方法选择昌黎县人民医院确诊子宫肌瘤的患者40例,给予小剂量米非司酮12.5 mg/d,口服1个月为1个疗程,连续服用3个疗程,观察服药前后子宫肌瘤体积、Hb含量和丙氨酸转氨酶(ALP)等指标的变化。结果治疗前子宫肌瘤平均体积为(12.44±6.50)cm3,治疗后子宫肌瘤平均体积为(5.91±3.65),治疗前后比较,差异有统计学意义(t=5.540,P<0.01);治疗前血红蛋白含量为(81.8±7.6)g/L g,治疗后血红蛋白含量为(95.2±7.7)g/L,治疗前后比较,差异亦有统计学意义(t=7.833,P<0.01);不良反应少,均无肝损害。结论小剂量米非司酮可以用于子宫肌瘤的保守治疗,改善贫血状况,提高女性生活质量,尤其适合围绝经期子宫肌瘤患者,疗效显著,值得应用和推广。

[ Objective] To analyze the clinical efficacy of low dose mifepristone in the treatment of hysteromyoma. [Methods] 40 patients with hysteromyoma in Changli Peoples Hospital were collected, and they were given hysteromyoma 12.5 mgld by oral administration. 1 month was 1 treatment course, and the study lasted for 3 courses. The changes of fibroid size, Hb concentration and ALP activity before and after medication were observed. [Results] The fibroid size before and after treatment was （12.44 ± 6. 50） cm3 and （5.91 ± 3.65） cm3 respectively, and the difference was significant （t = 5.540, P 〈0. 01）. Hb concentration before and after treatment was （81. 8 ± 7. 6） giL and （95.2 ± 7.7） giL respectively, and the difference was significant （t = 7. 833, P 〈0. 01）. There were less adverse reactions, and the liver damage was not found. [Conclusion] Low dose mifepristone can be used in the conservative treatment of hysteromyoma, which may improve anemia and enhance women s quality of life, and it is especially suitable for patients with hysteromyoma in perimenopausal period. The therapy has obvious curative effect, and is worth popularizing and applying.